RxDoctor Payments Data

Gregory Sepanski, MD

Ophthalmology · Auburn, ALNPI 1295748614

Payments from drug & device makers

$2,691in general payments, 2019–2025

Across 59 payments — averaging $45.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Glaukos Corporation$174
  • Bausch & Lomb Americas Inc.$173
  • AbbVie$107
  • NEW World Medical,inc.$77
  • Aerie Pharmaceuticals, Inc.$42
  • plus $126 from 6 others

What the payments were for

  • Food & beverage$2,66899%
  • Entertainment$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,691 in reported general payments places this provider in the 60th percentile of 197 ophthalmology providers in Alabama.

See all ophthalmology providers in Alabama

Medicare billing

Part B allowed, 2024
$367,459
Medicare patients
1,236
Services billed
2,754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost92$38,161
Prednisolone Acetate608$33,711
Latanoprost1,650$32,596
Travoprost105$23,111
XiidraLifitegrast29$22,310
Brimonidine Tartrate272$20,777
Timolol Maleate600$19,952
Cyclosporine31$15,666
MoxifloxacinMoxifloxacin Hcl442$14,567
CombiganBrimonidine Tartrate/Timolol35$10,557
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat363$10,308
Ketorolac Tromethamine428$9,369
RestasisCyclosporine11$8,148
RhopressaNetarsudil Mesylate17$7,874
SimbrinzaBrinzolamide/Brimonidine Tart25$7,611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$107$63,815159 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$173$29,59352 claims
Aerie Pharmaceuticals, Inc.Rhopressa$42$7,87417 claims
AlconSimbrinza$1,993$7,61125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 197 ophthalmology providers in Alabama.

Other ophthalmology in Auburn

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →